Silo Pharma Secures Exclusive License for PTSD Treatment Development

LOS ANGELES- Silo Pharma, Inc. a developmental stage biopharmaceutical company, has announced an exclusive global license agreement with Columbia University to develop, manufacture, and commercialize its lead drug candidate, SPC-15. This intranasal treatment targets stress-induced affective disorders and PTSD.

Exclusive License for SPC-15 Development

Silo Pharma has entered into an exclusive, global license agreement with Columbia University to further develop SPC-15, a novel treatment for PTSD and anxiety. This agreement allows Silo to advance its efforts in creating effective treatments for these disorders.

Regulatory Progress and FDA Interaction

Earlier this month, Silo submitted a pre-IND briefing package and meeting request for SPC-15 to the U.S. Food and Drug Administration (FDA). The company is in the final steps before submitting an Investigational New Drug (IND) application to begin first-in-human clinical studies. Silo plans to utilize the FDA’s 505(b)(2) pathway for SPC-15, which could shorten clinical timelines and reduce development costs.

CEO’s Statement on Shareholder Value

“In our opinion, the execution of the exclusive license agreement for our SPC-15 product is a critical step for our Company which we believe could increase shareholder value in the future, subject to FDA approval if and when received,” said Silo CEO Eric Weisblum.

About SPC-15

SPC-15 is a serotonin 4 (5-HT4) receptor agonist therapeutic, designed as an intranasal medication for the treatment of PTSD, anxiety, and other stress-induced affective disorders. If clinically successful, SPC-15 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway, expediting its approval process. Silo Pharma, in collaboration with Columbia University, is conducting preclinical studies and has been granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide.